Ritva Kauppinen1, Vesa Vilkka1, Harri Sintonen2, Jouni Hedman1. 1. Pulmonary Department, South Karelia Central Hospital, Lappeenranta, Finland. 2. Department of Public Health, University of Helsinki, Helsinki, Finland.
Abstract
BACKGROUND: An investigator-driven, real-life follow-up study of adult-onset steroid-naïve, newly diagnosed asthma (162 patients) to investigate the treatment results over the 25-year course of the disease and whether the first treatment year's forced expiratory volume in one second (FEV1 ) predicts the long-term prognosis. METHODS: Eighty-three per cent of the 133 living patients participated in the 25-year examinations. At this visit, basic asthma examinations including lung function, as well as questionnaires for health-related quality of life (HRQoL), GINA and the Asthma Control Test, were used for evaluation. The use of medication and remission was verified. RESULTS: There was no statistically significant change in mean FEV1 % predicted (FEV1 %) from baseline to the 25-year control. The changes in FEV1 % during the first year predicted the results at the end of follow-up. Normal FEV1 % at the end of the first year predicted normal FEV1 , and below-normal FEV1 % at 1 year predicted below-normal FEV1 % at 25 years. Twenty-nine patients (26.4%) had discontinued their medication, and six (5.5%) used ICS periodically. Clinical remission was reached by 16.4% of the patients, and 7.6% reached functional remission. The general HRQoL remained unchanged. CONCLUSION: In adult-onset asthma, the level of FEV1 reached during the first treatment year seems to predict the later lung function level. One quarter of the patients discontinued the asthma treatment, but their HRQoL was better than that of those continuing to use ICS. Clinical remission was reached by 16% of the patients, which is in concordance with other studies.
BACKGROUND: An investigator-driven, real-life follow-up study of adult-onset steroid-naïve, newly diagnosed asthma (162 patients) to investigate the treatment results over the 25-year course of the disease and whether the first treatment year's forced expiratory volume in one second (FEV1 ) predicts the long-term prognosis. METHODS: Eighty-three per cent of the 133 living patients participated in the 25-year examinations. At this visit, basic asthma examinations including lung function, as well as questionnaires for health-related quality of life (HRQoL), GINA and the Asthma Control Test, were used for evaluation. The use of medication and remission was verified. RESULTS: There was no statistically significant change in mean FEV1 % predicted (FEV1 %) from baseline to the 25-year control. The changes in FEV1 % during the first year predicted the results at the end of follow-up. Normal FEV1 % at the end of the first year predicted normal FEV1 , and below-normal FEV1 % at 1 year predicted below-normal FEV1 % at 25 years. Twenty-nine patients (26.4%) had discontinued their medication, and six (5.5%) used ICS periodically. Clinical remission was reached by 16.4% of the patients, and 7.6% reached functional remission. The general HRQoL remained unchanged. CONCLUSION: In adult-onset asthma, the level of FEV1 reached during the first treatment year seems to predict the later lung function level. One quarter of the patients discontinued the asthma treatment, but their HRQoL was better than that of those continuing to use ICS. Clinical remission was reached by 16% of the patients, which is in concordance with other studies.
Authors: Hanna Hisinger-Mölkänen; Jasmin Honkamäki; Hannu Kankaanranta; Leena Tuomisto; Helena Backman; Heidi Andersen; Ari Lindqvist; Lauri Lehtimäki; Anssi Sovijärvi; Eva Rönmark; Paula Pallasaho; Pinja Ilmarinen; Päivi Piirilä Journal: World Allergy Organ J Date: 2022-09-16 Impact factor: 5.516